SCT scientists develop Neo-Islet technology for treating insulin-dependent diabetes

The cover of the July 2017 issue of the journal STEM CELLS Translation Medicine showcases the latest advance toward a functional cure of insulin-dependent diabetes. Scientists at SymbioCellTech (SCT), a small biotech company in Salt Lake City, developed a technology that combines Mesenchymal Stem Cells (MSCs) with culture-expanded pancreatic islet cells to form three-dimensional cellular clusters, termed “Neo-Islets”. A single dose of Neo-Islets administered into the abdominal cavity provides durable blood sugar control, i.e., insulin-independence, without the need for potentially toxic anti-rejection drugs or encapsulation devices.

Type-1 diabetes is an auto-immune disease in which the patient’s own immune system attacks and destroys the islet cells in the pancreas resulting in the inability of the body to produce insulin. The standard cell therapy for diabetes is islet cell transplantation into the liver; however, this approach has serious drawbacks: (1) it requires the patient to permanently take potentially-toxic immunosuppression drugs, (2) it cannot be scaled up to treat the large number of patients that would benefit from this therapy because up to 5 donor pancreata are required for a single dose, and (3) it is expensive. In order to avoid the need for immunosuppressive agents, researchers have focused on using various devices that encapsulate islets or other insulin-producing cells. These devices, made of specially-formulated materials, are designed to protect against the immune attack yet allow for glucose-sensitive insulin release. Limited success with this technology has been observed in the lab, but most encapsulation devices have failed due to foreign body reactions.

Read more

Stocks To Consider As Profit-Taking Accelerates In Technology Sector

Technology stocks, which account for the lion’s share of Nasdaq Composite index and include heavyweights like Apple, Alphabet, and Microsoft, are facing heavy sell-off this June after posting double-digit gains for the year.

The tech-sector correction, which started in the second week of June, gained further momentum this Thursday, reflecting in some of the biggest single-day losses in the S&P 500 Technology Index (down 1.8%) and the tech-heavy Nasdaq Composite (down 1.4%).

Read more

What To Expect From Aphria Inc’s (TSX:APH) Earnings Over The Next Year?

As per analysts covering Aphria Inc (TSX:APH) the earnings are expected to decrease -32.9% in the next 12 months. However, investors must be concerned whether it’s just a hiccup or a long-term trend. Today I’m going research the future of this stock in more detail.

Not very exciting times ahead
The next year is a potential rough ride for Aphria. This is if you believe 4 analysts who expect the new EPS to be $0.13, a major change from previous levels of $0.09. In percentage terms this is a reduction of -32.9% so it will certainly be interesting to be a shareholder in this time.

Read more

Ondek raises capital to develop new treatment for childhood allergy

Ondek, the Australian biotechnology company founded by Nobel Laureate Professor Barry Marshall, today announced it raised A$3.59 million in equity funding from professional and high-net-worth investors to support his work to develop a new treatment for childhood allergy.

Ondek is seeking to develop a new immunotherapy based on the bacterium Helicobacter pylori.  The company has patented a killed derivative of H. pylori to be developed as a natural and safe immunotherapy named ImmBALANCE®.

Read more

Evaporative Sample Preparation for Mass Spectrometry

Genevac has established a new web page that brings together customer technical articles that illustrate how centrifugal evaporation has become a sample preparation technique of choice for laboratories that seek to analyse complex samples using hyphenated mass spectrometry [MS] techniques.

Many laboratories still rely upon the use of a rotary evaporator to perform the evaporation part of their sample preparation protocol prior to LC-MS or GC-MS analysis. While rotary evaporator methods often give good recoveries, they can only handle a single sample, require continuous monitoring to control the process and to ensure that no foaming or bumping occurs.

Read more

Managing nutrition leads to feedlot gains

A new feeding programme designed by biotech company Alltech shows that with proper timing, nutrition can be a more powerful tool than genetic manipulation for controlling production, animal health and quality.

Alltech’s nutritional programme Epnix has yielded increased carcase weight, dressed yield and ribeye area in large scale trials, and it has been seen to remove antibiotics.

Read more

The New England region is set to become a hub for the growing ag-tech sector.
Armidale has been selected to host one of three pilot projects, or ‘clusters’, which aim to deliver rural innovation and create jobs for the future.

“When similarly minded businesses work in close proximity with one another – it’s not only more efficient, but leads to greater productivity and improved working life compared to entrepreneurs going it alone,” Member for Northern Tablelands Adam Marshall said

The new ‘Cluster Champion’, Chris Celovic, will work with small and medium-sized businesses, as well as turning his attention to the global marketplace.

Read more

Global Alpha-Amylase (α-Amylase) Market Research Report 2017

The Alpha-Amylase (α-Amylase) Industry Market Research Report 2017 is a professional and in-depth study on the current state of the Alpha-Amylase (α-Amylase) industry.

Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Alpha-Amylase (α-Amylase) market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status.

Read more

What To Expect From Bio-Techne Corporation’s (TECH) Earnings Over The Next Year?

Analysts covering Bio-Techne Corporation (NASDAQ:TECH) are predicting the earnings to grow 25% in years’ time. What should potential investors be aware of? Today I will look at the latest data and investigate into the future of this high growth stock in more detail.

Exciting times ahead for TECH
Investors in Bio-Techne have been patiently waiting for the uptick in earnings and if you believe the 5 analysts covering the stock then the next 3 years will be very interesting. The estimates for earnings per share range from $2.62 to $3.17 with an average expectation of 65.4% growth.

Read more

Students fly high for Coast farmers

AN INNOVATIVE Sunshine Coast school which is using cutting-edge agricultural technologies has received a major boost to further their studies.

Queensland Minister for Innovation, Science and the Digital Economy Leeanne Enoch said Beerwah’s Glasshouse Christian College received an Advance Queensland Engaging Science Grant for its AgriTech project involving students, local fruit and vegetable growers, state-of-the-art remote sensing technologies and drones.

Read more